PROSIEBENSAT1 MED. (OTCMKTS:PBSFF) has earned a consensus recommendation of “Hold” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating on the company.

Several research firms have recently weighed in on PBSFF. DZ Bank AG reiterated a “sell” rating on shares of PROSIEBENSAT1 MED. in a research report on Wednesday, April 19th. BNP Paribas downgraded PROSIEBENSAT1 MED. from an “outperform” rating to a “neutral” rating in a research report on Friday, July 7th. Finally, Citigroup Inc. reiterated a “neutral” rating on shares of PROSIEBENSAT1 MED. in a research report on Tuesday, May 9th.

PROSIEBENSAT1 MED. (PBSFF) remained flat at $37.82 during midday trading on Tuesday. The stock has a 50-day moving average of $39.85 and a 200 day moving average of $41.58. PROSIEBENSAT1 MED. has a 1-year low of $33.70 and a 1-year high of $45.81. The firm has a market cap of $8.65 billion and a P/E ratio of 18.24.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at


Analyst Recommendations for PROSIEBENSAT1 MED. (OTCMKTS:PBSFF)

Receive News & Ratings for PROSIEBENSAT1 MED. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROSIEBENSAT1 MED. and related companies with's FREE daily email newsletter.